Latest Articles
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer - Cancer Health Treatment News
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer Cancer Health Treatment News
Published: June 20, 2024, 7 a.m.
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer - Medpage Today
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer Medpage Today
Published: June 18, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology
FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology
Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review
Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review
Published: June 18, 2024, 7 a.m.
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval - FiercePharma
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval FiercePharma
Published: June 18, 2024, 7 a.m.
Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer - PMLiVE
Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer PMLiVE
Published: June 18, 2024, 7 a.m.
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma - AJMC.com Managed Markets Network
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma AJMC.com Managed Markets Network
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology
Published: June 17, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central
Published: June 17, 2024, 7 a.m.
AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer - PMLiVE
AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer PMLiVE
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!